Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

ClinicalTrials.gov ID: NCT03444038

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03444038. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-Label Safety and Tolerability Study of Optimized Doses of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome.

Study identification

NCT ID
NCT03444038
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
85 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
6 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 8, 2018 (Actual)
Primary completion
Jul 12, 2019 (Actual)
Completion
Jul 12, 2019 (Actual)
Last update posted
Feb 23, 2022

2018 – 2019

United States locations

U.S. sites
36
U.S. states
19
U.S. cities
34
Facility City State ZIP Site status
Neurocrine Clinical Site Sun City Arizona 85351 —
Neurocrine Clinical Site Anaheim California 92805 —
Neurocrine Clinical Site San Diego California 92108 —
Neurocrine Clinical Site Santa Ana California 92705 —
Neurocrine Clinical Site Santa Clarita California 91321 —
Neurocrine Clinical Site New Haven Connecticut 06510 —
Neurocrine Clinical Site Boca Raton Florida 33431 —
Neurocrine Clinical Site Gulf Breeze Florida 32561 —
Neurocrine Clinical Site Hialeah Florida 33013 —
Neurocrine Clinical Site Orlando Florida 32801 —
Neurocrine Clinical Site Orlando Florida 32803 —
Neurocrine Clinical Site St. Petersburg Florida 33701 —
Neurocrine Clinical Site Tampa Florida 33614 —
Neurocrine Clinical Site Chicago Illinois 60634 —
Neurocrine Clinical Site Naperville Illinois 60563 —
Neurocrine Clinical Site Iowa City Iowa 52242 —
Neurocrine Clinical Site Leawood Kansas 66206 —
Neurocrine Clinical Site Ann Arbor Michigan 48105 —
Neurocrine Clinical Site Bloomfield Hills Michigan 48371 —
Neurocrine Clinical Site St Louis Missouri 63110 —
Neurocrine Clinical Site Lincoln Nebraska 68526 —
Neurocrine Clinical Site Nashua New Hampshire 03060 —
Neurocrine Clinical Site Mount Arlington New Jersey 07856 —
Neurocrine Clinical Site Voorhees Township New Jersey 08043 —
Neurocrine Clinical Site New York New York 10036 —
Neurocrine Clinical Site The Bronx New York 10467 —
Neurocrine Clinical Site Durham North Carolina 27705 —
Neurocrine Clinical Site Mason Ohio 45040 —
Neurocrine Clinical Site Oklahoma City Oklahoma 73112 —
Neurocrine Clinical Site Charleston South Carolina 29414 —
Neurocrine Clinical Site Dallas Texas 75243 —
Neurocrine Clinical Site Houston Texas 77030 —
Neurocrine Clinical Site Houston Texas 77058 —
Neurocrine Clinical Site San Antonio Texas 78249 —
Neurocrine Clinical Site Everett Washington 98201 —
Neurocrine Clinical Site Tacoma Washington 98405 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03444038, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 23, 2022 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.